This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology Health Care Health Diagnostics Life Science Medical Device North America

Truvian Sciences Raises More Than $105M in Series C Financing

– Truvian Sciences, a San Diego, CA-based closed more than $105m in a Series C financing.
– The round was led by TYH Ventures, Glen Tullman of 7wireVentures, and Wittington Ventures.
– The company intends to use the funds to advance development of its automated benchtop blood testing system, paving the way to submit the device for U.S. Food and Drug Administration (FDA) clearance, and to scale its team in preparation for broad commercialization.
– Truvian is a healthcare company at the intersection of diagnostics and consumer technology.

Biotechnology Health Care Health Diagnostics Life Science Medical Device North America

Truvian raises $105 million to commercialize its automated blood-testing platform

– San Diego, California-based Truvian, a startup developing blood-testing technology that leans heavily on automation, today announced the close of an over $105 million oversubscribed series C round led by TYH Ventures, 7wireVentures’ Glen Tullman, and Wittington Ventures.
– Truvian says the funds will advance development of its benchtop blood testing system and enable the company to grow its product development team.
– More than 13 billion tests are performed in over 250,000 labs in the U.S. each year, and errors related to lab testing are more common than you might think. A 2014 study estimated that diagnostic errors for U.S. outpatients occur about 12 million times per year.

Agriculture AgTech Biotechnology Life Science North America

Terra Vera Raises $2 Million in Seed Funding Round

– Terra Vera closed a $2m seed funding round, exceeding its original goal by an additional $500k or 33%.
– The company will use the capital to complete the transition from its proof-of-concept phase, introduced in 2020 through work with select clients, to a full-fledged commercial market rollout of its services and non-toxic crop management technologies.
– Terra Vera’s electrolysis-based tech is a game-changer for growers in industries including cannabis, wine, beer, food systems and more.
– In addition, Terra Vera’s experienced team is working closely to ensure their agricultural solutions are compliant with state-specific regulations.

Biotechnology Europe Health Care Life Science

Orna Therapeutics Launches With $80M Series A

– Orna Therapeutics, a biotechnology company dedicated to RNA therapeutics (oRNAs), announced the completion of its $80m Series A financing.
– The financing was co-led by MPM Capital, Taiho Ventures, and F2 Ventures, with participation from leading strategic investors: Kite, a Gilead Company, Bristol Myers Squibb, Astellas Venture Management, Novartis Institutes for Biomedical Research, and the PAGS Group.
– Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way disease is treated.

Biotechnology Health Care Health Diagnostics Life Science North America

Micronoma Closes $3.5M Convertible Debt Financing Round

– Micronoma is a San Diego, Calif.-based cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology.
– The company closed a $3.5m convertible debt financing round.
– Backers included SymBiosis, LLC and The Seerave Foundation.
– The investments bring the company’s total amount of funding to $6.5m since the first seed round six months ago.

Biopharma Biotechnology Life Science Machine Learning Manufacturing North America

AbSci Announces Strategic Investment

– AbSci announced a strategic equity investment by Merck Global Health Innovation Fund.
– Merck GHI is a fund of Merck Research Laboratories.
– AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process.

Biotechnology Health Care Health Diagnostics Life Science North America

Fred Hutch biotech spinout Ozette raises $6M from Madrona, AI2, Vulcan

– Ozette, a biotech company, raised $6m in seed funding.
– The round was led by Madrona Venture Group and joined by AI2 and Vulcan.
– The company has eight employees with plans to double that number in the next few months with the fresh cash.
– Ozette’s founders estimate that in the past, researchers were able to analyze 10% of the information revealed by their studies. Their tool brings that up to 100%.

Biotechnology Chemical Chemical Engineering Europe Life Science

EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden

– EnginZyme has extended its Series A to €11m and raised the total to €11m.
– The extension round was led by Industrifonden, Sweden’s largest deep tech venture capital firm, followed by SEB Greentech VC and existing shareholders.
– EnginZyme is developing a technology platform for sustainable production of chemicals.
– The company has produced catalysts at multi-kilogram scales and operated pilots capable of producing 50 tons per year of product.
– This year will see the company pilot production processes and advance partnerships across markets such as high-performance cosmetics, food applications, alternative sweeteners, and flavors and fragrances.

Asia Biotechnology Life Science

Neurophth Closes RMB 400 Million Series B Financing

– Neurophth Biotechnology Ltd. announced the closing of a RMB 400 million ($61.9 million USD) Series-B financing with a premier syndicate of investors, co-led by Guofang Capital and InnoVision Capital.
– Neurophth is a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases.
– The company has an extensive portfolio of potentially curative gene therapies for the treatment of ocular genetic diseases.

Crunchbase icon

Content report

The following text will be sent to our editors: